Related references
Note: Only part of the references are listed.Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial
Ralf U. Trappe et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Hepatitis C treatment: where are we now?
Nicholas J. Burstow et al.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2017)
Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer
M. P. Economides et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features
J. Finalet Ferreiro et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Direct acting antivirals for decompensated cirrhosis. Efficacy and safety are now established
Michael P. Curry
JOURNAL OF HEPATOLOGY (2016)
Post-transplant lymphoproliferative disorders
Vikas R. Dharnidharka et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options
Gabriele Pozzato et al.
WORLD JOURNAL OF HEPATOLOGY (2016)
Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations
Harrys A. Torres et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now?
Daan Dierickx et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: A Flood of Opportunity''
E. J. Gane et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
Challenges in managing hepatitis C virus infection in cancer patients
Roy A. Borchardt et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management
Jan Peveling-Oberhag et al.
JOURNAL OF HEPATOLOGY (2013)
Current and Future Therapies for Hepatitis C Virus Infection
T. Jake Liang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies
Zeina Al-Mansour et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
Ralf Trappe et al.
LANCET ONCOLOGY (2012)
Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder
R. Reshef et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Posttransplant lymphoproliferative disease following liver transplantation
Kala Y. Kamdar et al.
CURRENT OPINION IN ORGAN TRANSPLANTATION (2011)
Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis
Daisuke Ennishi et al.
BLOOD (2010)
Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era
Andrew M. Evens et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Primary central nervous system lymphoma
Lauren E. Abrey
CURRENT OPINION IN NEUROLOGY (2009)
Laboratory assays for Epstein-Barr virus-related disease
Margaret L. Gulley et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
Prospective study of sequential reduction in immunosuppression, interferon alpha-2b, and chemotherapy for posttransplantation lymphoproliferative disorder
Lode J. Swinnen et al.
TRANSPLANTATION (2008)
Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy
Daisuke Ennishi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients
Lindsay M. Morton et al.
BLOOD (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation
Sylvain Choquet et al.
HAEMATOLOGICA (2007)
Posttransplant lymphoproliferative disorder in adult liver transplant recipients: A report of seventeen cases
Himisha Patel et al.
LEUKEMIA & LYMPHOMA (2007)
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders:: results of a prospective multicenter phase 2 study
S Choquet et al.
BLOOD (2006)
Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)
SHK Oertel et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphoma in South Florida and review of the literature
D Morgensztern et al.
LEUKEMIA & LYMPHOMA (2004)
Posttransplant lymphoma - A single-center experience of 500 liver transplantations
S Norin et al.
MEDICAL ONCOLOGY (2004)
Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies
T Kawatani et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2001)
Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders
V Leblond et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
